TriStar StoneCrest
January 13, 2021

Jenni Gleason, RN, prepares Bam Infusion Room at TriStar StoneCrest Medical Center

Smryna, Tenn.  – TriStar StoneCrest Medical Center is proud to announce it has started administering the monoclonal antibody therapeutic, bamlanivimab, for the treatment of non-hospitalized patients with mild or moderate confirmed cases of COVID–19. Bamlanivimab received emergency use authorization from the U.S. Food and Drug Administration (USFDA) on November 9, 2020.

“TriStar StoneCrest is committed to providing excellent, high–quality patient care and by offering the monoclonal antibody therapy bamlanivimab our hospital can provide hope to the community while making a direct impact in the fight against COVID–19,” says Joe Gleason, chief operating officer at TriStar StoneCrest Medical Center. “As a part of HCA Healthcare, one of the nation’s leading providers of healthcare, we are proud to have the resources to provide support and solutions to our patients, colleagues and communities, including the latest approved treatments for COVID–19.”

According to the USFDA, bamlanivimab is appropriate for emergency use for the treatment of mild to moderate COVID–19 in adults and pediatric patients with positive results of direct SARS–CoV–2 viral testing who are 12 years of age or older weighing at least 40 kg (88 lbs.), and who are at high risk for progressing to severe COVID–19 and/or hospitalization. High-risk criteria include:

  • Have a body mass index (BMI) ≥ 35
  • Have chronic kidney disease
  • Have diabetes mellitus
  • Have immunosuppressive disease
  • Are currently receiving immunosuppressive treatment
  • Are ≥ 65 years of age
  • Are ≥ 55 years of age AND
  • Have cardiovascular disease, or hypertension or, chronic obstructive pulmonary disease/other chronic respiratory disease.
  • Are 12 – 17 years of age AND have
  • BMI ≥85th percentile for their age and gender based on CDC growth charts, or https://www.cdc.gov/growthcharts/clinical_charts.htm
  • Sickle cell disease,
  • Congenital or acquired heart disease,
  • A neurodevelopmental disorders, for example, cerebral palsy,
  • A medical-related technological dependence, for example, tracheostomy, gastrostomy, or  positive pressure ventilation (not related to COVID-19),
  • Asthma, reactive airway or other chronic respiratory disease that requires daily medication for control.

“The approval of bamlanivimab is an important step in the fight against COVID-19 and reducing hospitalizations related to the virus,” added Gleason. “We are excited to provide the bamlanivimab treatment option to adult’s age 18 years and over. We are one of two HCA TriStar Division hospitals, the other being TriStar Southern Hills, and the only facility in Rutherford County that will be working closely with physicians and other providers across the communities we serve to provide this treatment option to patients who may benefit, per the FDA guidelines.”

Patients must obtain a physician referral for a BAM Infusion Consult from a TriStar StoneCrest Medical Center pulmonologist, meet FDA criteria prior to scheduling, and have a referral order for BAM Infusion. Patients who meet the criteria for treatment will be referred for outpatient treatment at the BAM infusion therapy center located at TriStar StoneCrest Medical Center. This is a three–hour treatment process.

For additional information about monoclonal antibody therapy bamlanivimab, go to TriStar Health.com/StoneCrest or call (615) 768-2855.

About TriStar StoneCrest Medical Center

Celebrating 17 years of serving the community, TriStar StoneCrest Medical Center is a 119-bed facility located in North Rutherford County, Tenn. The TriStar Health hospital offers a full array of acute care services, including emergency care, general surgery, cardiology, obstetrics including a level 2 NICU, intensive care, vascular, neurology, sleep, breast, urology, urogynecology, physical medicine, outpatient diagnostic service, podiatry, orthopedics, joint, spine, otorhinolaryngology, and cancer care through Sarah Cannon at TriStar StoneCrest. Recognized as a Joint Commission Top Performer in Key Quality Measures for four consecutive years, recipient of the Blue Distinction® Center for Knee and Hip Replacement, and an accredited Center of Excellence in Hernia center by the Surgical Review Corporation. TriStar StoneCrest maintains its commitment to be the center of excellence for a national leader in providing quality healthcare. The facility is also an Accredited Chest Pain Center, Certified Primary Stroke Center and recognized by American College of Surgeons Commission on Cancer Accreditation. For more information visit TriStarHealth and click on TriStar StoneCrest.

About TriStar Health

TriStar Health is the largest, most comprehensive healthcare provider in Middle Tennessee and Southern Kentucky, supporting over 430,000 patients and nearly 453,000 emergency room visits annually. TriStar Health comprises 10 hospitals, 14 emergency rooms, 21 imaging locations, 14 CareNow Urgent Care centers, 57 TriStar Medical Group provider office locations and related care areas conveniently located in communities around the region. Sarah Cannon Cancer Institute at TriStar Health, part of HCA’s global network of cancer experts, offers a full range of services for prevention, diagnosis and treatment of cancer, as well as comprehensive rehabilitation. Additional specialty care includes pediatric services provided through The Children’s Hospital at TriStar Centennial, advanced cardiology services provided through TriStar Centennial Heart & Vascular Center, and behavioral health services provided through TriStar Centennial Parthenon Pavilion and TriStar Skyline Madison Campus. Services are supported by over 1,600 physicians and nearly 9,500 employees – including nearly 3,800 nurses - who, above all else, are committed to the care and improvement of human life. TriStar Health is an affiliate of HCA, one of the nation’s leading providers of healthcare services. Learn more at TriStarHealth.com.